Aurora Cannabis (ACB) Net Income towards Common Stockholders (2017 - 2026)
Aurora Cannabis (ACB) posted quarterly Net Income towards Common Stockholders of $5.6 million for Q1 2026, down 63.46% year-over-year from $15.3 million in Q1 2025, and down 52.34% quarter-over-quarter from $11.7 million in Q4 2025.
Aurora Cannabis (ACB) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Aurora Cannabis (ACB) has reported Net Income towards Common Stockholders for 10 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 63.46% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $802.1 million (down 35.01% YoY), while the FY2026 annual figure was -$42.7 million, down 110.48% from the prior year.
- Net Income towards Common Stockholders retreated to $5.6 million in Q1 2026 per ACB's latest filing, from $11.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $410.6 million in Q2 2024 and bottomed at -$1.3 billion in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged $39.4 million across 5 years, with a median of $354.2 million in 2023.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 4195.43% — and 2025, when it jumped 1023.24%.
- Aurora Cannabis' Net Income towards Common Stockholders stood at -$545.4 million in 2022, then soared by 169.56% to $379.4 million in 2023, then rose by 8.11% to $410.1 million in 2024, then slumped by 97.14% to $11.7 million in 2025, then slumped by 52.34% to $5.6 million in 2026.
- Business Quant data shows ACB's Net Income towards Common Stockholders at $5.6 million in Q1 2026, $11.7 million in Q4 2025, and $386.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Aurora Cannabis | 233.45 Mn | 161.14 Mn | 25.75 Mn | -2.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.58 Mn |
| Dec 31, 2025 | 11.71 Mn |
| Sep 30, 2025 | 386.51 Mn |
| Jun 30, 2025 | 398.33 Mn |
| Mar 31, 2025 | 15.27 Mn |
| Dec 31, 2024 | 410.12 Mn |
| Sep 30, 2024 | 398.17 Mn |
| Jun 30, 2024 | 410.62 Mn |
| Mar 31, 2024 | -1.65 Mn |
| Dec 31, 2023 | 379.35 Mn |
| Sep 30, 2023 | 375.79 Mn |
| Jun 30, 2023 | 354.16 Mn |
| Mar 31, 2023 | 359.55 Mn |
| Dec 31, 2022 | -545.38 Mn |
| Sep 30, 2022 | -515.60 Mn |
| Jun 30, 2022 | -488.98 Mn |
| Mar 31, 2022 | -1.28 Bn |
| Dec 31, 2021 | 1.55 Bn |
| Sep 30, 2021 | -12.00 Mn |
| Jun 30, 2021 | -87.26 Mn |